Thursday, January 29, 2015

Eyegate Pharmaceuticals, Inc. (EYEG) Developing New Delivery System and Treatment for Ocular Conditions

Eyegate Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutics and drug delivery systems for the treatment of diseases of the eye. Through its exclusive EyeGate® II Delivery System, Eyegate Pharma is currently developing its first and only drug candidate, EGP-437, which incorporates a reformulated topically active corticosteroid that is delivered directly into the ocular tissues of patients for the treatment of a variety of infections and diseases.

The company’s proprietary drug delivery system is designed to address two major issues in ophthalmic medicine, which include lack of patient compliance and safety. Featuring a compact, elegant and easy-to-use device, the EyeGate® II Delivery System is designed to deliver drugs non-invasively through the use of iontophoresis. The company’s specialized delivery system has been shown to accelerate the onset of action, dramatically reduce treatment frequency and sustain the therapeutic effects of treatments. The easy-to-use device has already been utilized to effectively administer more than 1,700 experimental treatments, including more than 1,000 treatments of the company’s EGP-437. With worldwide commercialization rights in hand, the company is aiming to fill a growing unmet medical need and provide physicians with a responsible solution to the treatment of increasingly common ophthalmic diseases.

The company’s leading candidate, EGP-437, is currently in Phase III trials for the treatment of anterior uveitis, which is a debilitating form of inflammation involving the middle layer of the eye. The initial data from the drug candidate’s trials revealed it as similarly effective to the currently available standard of care. The company expects the trials to be completed by the first half of 2016. In addition, Eyegate Pharma intends to expand the use of EGP-437 to other inflammatory eye conditions, such as dry eye and cataract surgery. Among other advantages, the company believes that patients may benefit from the potential elimination of demanding dosing schedules, rapid relief of symptoms, increased comfort and reduced side effects through the use of its drug candidate in combination with its specialized delivery system.

With the market for uveitis currently being dominated by branded and generic prednisolone eye drops that are ineffective in 50%-60% of patients, the potential for a new drug option in the sector is promising. With the company’s IPO of 1.4 million shares of common stock, Eyegate Pharma looks to raise capital while continuing towards the future commercialization of its leading drug candidate and non-invasive drug delivery system.

For more information, visit www.eyegatepharma.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: